

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Keener et al.

Serial No.:

Filed: Herewith

For: SELECTIVE DESTRUCTION OF
CELLS INFECTED WITH HUMAN
IMMUNODEFICIENCY VIRUS

Examiner: J. Stucker

Group Art Unit: 3748

Attorney Docket No.: LIT-PI-529D1

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

7/10/03
Date of Deposit

Mandy Landon
Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Mandy Landon
Typed/printed name of person whose signature is contained above

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed before the first Office Action on Merits and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Stephen R. Christian", with a stylized flourish at the end.

Stephen R. Christian
Registration No. 32,687
Attorney for Applicants
P.O. Box 1625
Idaho Falls, ID 83415-3899
Phone: (208) 526-9140
Fax: (208) 526-8339

Date: July 10, 2003
Enclosures: PTO/SB/08
Cited Documents

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529D1		SERIAL NO. Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener			
				FILING DATE Filed Herewith		GROUP Unknown	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5591829	01/07/97	Matsushita	530	391.1	
	AB	5633388	05/27/97	Diana et al	514	393	
	AC	5645836	07/08/97	Kitto	424	159.1	
	AD	5677274	10/14/97	Leppla et al	514	2	
	AE	5684024	11/04/97	Diana et al	548	365.4	
	AF	5767072	06/16/98	Vitetta et al	424	194.1	
	AG	5821243	10/13/98	Diana et al	544	238	
	AH	5830894	11/03/98	Pevear et al	514	243	
	AI	5834599	11/10/98	Chang et al	530	388.35	
	AJ	5935957	8/10/99	Diana et al	514	247	
	AK	6333303	12/25/01	Borgford	514	2	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
	AL	WO97/41233	11/6/97	PCT			
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
	AR		Lord, J.M., et al, "Ricin: Structure, Mode of Action, and Some Current Applications", <u>The FASEB Journal</u> , Vol.8 pp. 201 and 206, 2/94.				
			Richardson, P.T, et al, "Recombinant Proricin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA," <u>FEBS 07564</u> , Vol 255, No. 1, page 15, 9/89.				
	AS		Westby, M.W., et al, "Preparation and Characterization of Recombinant, Proricin Containing an Alternative Protease-Sensitive Linker Sequence," <u>Bioconjugate Chemistry</u> , 1992, 3, p. 375.				
			Darket, P.L., et al., "Human Immunodeficiency Virus Protease," <u>Journal of Biological Chemistry</u> , Vol 264, No. 4, p. 2307 1989.				
	AT		Jordan, S.P., et al, "Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 28, p. 20028. 1992.				
			Van Quen, M.G., "Rationale for the Use of Immunotoxins in the Treatment of HIV-Infected Humans," <u>Journal of Drug Targeting</u> , Vol 5, No. 2 p. 75, 1997.				
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529	SERIAL NO. Filed Herewith		
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener, et al			
				FILING DATE Filed Herewith		GROUP Unknown	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
	AR		Wachinger, M., et al, "Bryodin, a Single-Chain Ribosome-Inactivating Protein, Selectively Inhibits the Growth of HIV-1-Infected Cells and Reduces HIV-1 Production," <u>Research in Experimental Medicine</u> , 193:1-2, 1993.				
			Till, M.A., et al, "HIV-Infected Cells are Killed by rCF4-Ricin A Chain," <u>Science</u> , Vol. 24 p. 1166.				
	AS						
	AT						
EXAMINER				DATE CONSIDERED			
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>							